A heightened focus on value is driving efforts across health care to improve outcomes and reduce costs. For pharmaceutical companies, this focus translates into a shift away from traditional payment models to more outcomes-based, risk sharing agreements. In many ways, these agreements present the opportunity to better align interests across health care’s stakeholders. However, they[…]
Value-based care is gaining momentum and with that so too are outcomes-based contracts and risk sharing agreements. As payment models increasingly link outcomes to payment, there is a greater need for alignment of outcomes among different stakeholders. Join Dr. Richard Gliklich as he discusses the opportunities and challenges with: Defining measurable outcomes Developing and implementing[…]
The needs for real-world evidence continue to grow, but so have the tools. This session will explore the changes in technology, data liquidity, healthcare economics and how they are all combining to change the needs for real-world evidence and the best means to collect, analyze and use it. While registries remain an important component of[…]
